10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 25,000 Shares of Company Stock

Posted by Geri Gentry on Sep 25th, 2026

10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 25,000 shares of 10x Genomics stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total value of $2,030,500.00. Following the completion of the sale, the chief executive officer owned 1,050,249 shares of the company’s stock, valued at $85,301,223.78. The trade was a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Serge Saxonov also recently made the following trade(s):

On Wednesday, August 26th, Serge Saxonov sold 10,486 shares of 10x Genomics stock. The shares were sold at an average price of $63.69, for a total transaction of $667,853.34.
On Monday, August 24th, Serge Saxonov sold 18,545 shares of 10x Genomics stock. The shares were sold at an average price of $63.02, for a total transaction of $1,168,705.90.

10x Genomics Stock Performance

NASDAQ TXG opened at $84.11 on Friday. The company has a market cap of $10.96 billion, a PE ratio of -142.56 and a beta of 2.08. The firm’s 50 day moving average price is $59.90 and its 200-day moving average price is $38.61. 10x Genomics has a 52-week low of $11.16 and a 52-week high of $85.93.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. The company had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. 10x Genomics’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.28 earnings per share. On average, analysts forecast that 10x Genomics will post -0.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

TXG has been the topic of several analyst reports. Morgan Stanley lifted their target price on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Barclays lifted their price objective on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Canaccord Genuity Group increased their target price on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a report on Monday. Finally, TD Cowen reaffirmed a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $44.00.

View Our Latest Stock Analysis on TXG

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors have recently modified their holdings of the business. Sei Investments Co. increased its position in shares of 10x Genomics by 113.5% in the first quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock valued at $949,000 after buying an additional 23,748 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in 10x Genomics in the 1st quarter valued at $5,945,000. Clough Capital Partners L P purchased a new stake in 10x Genomics in the 4th quarter worth $9,955,000. Squarepoint Ops LLC acquired a new position in 10x Genomics during the second quarter worth $2,069,000. Finally, Proficio Capital Partners LLC acquired a new position in 10x Genomics during the second quarter worth $781,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, Visium solutions for spatial transcriptomics and tissue profiling, and Xenium in situ platforms for high-resolution analysis of RNA and other biological features within tissue samples.